News Releases

News and information from The Leukemia & Lymphoma Society

LLS AND BURLINGTON STORES HAVE RAISED MORE THAN $29 MILLION TO FIGHT CANCER

Rye Brook, NY (December 13, 2016) – Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) Light The Night Walk® campaign collaborated for the 15th consecutive year to shine a light on the urgent need for funding to help support blood cancer research and advance new treatments and cures. From September 7 through November 30, all Burlington Stores nationwide encouraged customers to donate to the cause ...

New Research for the Holidays Shows It Is Better to Give Than Receive

View full multimedia release here Rye Brook, NY Nov. 30, 2016 – A new national survey by The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary health non-profit dedicated to fighting blood cancers, finds that an overwhelming majority of Americans (90%) say they believe the true meaning of the holidays is to help others and 87% say they wish they could do more to help others in need. Eight in...

LLS Receives Prestigious Innovation Impact Award to “Reach the Unreached”

Rye Brook, NY – November 30, 2016 – The Leukemia & Lymphoma Society (LLS) was awarded the 2016 Celgene Innovation Impact award for an initiative that will allow the organization to “Reach the Unreached” with education and support for blacks, who are at twice the risk for multiple myeloma as whites. LLS’s initiative, “Taking it to Church: Enhancing Myeloma Knowledge and Access to Latest Treatments i...

LLS Invests $40.3 Million in New Research to Find Cures

View full multimedia release here   Rye Brook, NY – November 16, 2016 – The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cance...

MD Anderson Starts LLS-Funded Clinical Trial for Acute Myeloid Leukemia

Houston, TX- October 26, 2016 -- The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759. The study will enroll patients with acute myeloid leukemia (AML) and is supported by a $3.5 million investment from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Progr...

LLS Launches Groundbreaking Precision Medicine Approach to Treat AML

View full multimedia release here View media toolkit here As Announced Yesterday By Vice President Joe Biden, LLS to Lead First-Ever Blood Cancer Master Trial With Unprecedented Collaboration Between World-Renowned Researchers and Medical Centers, Biopharmaceutical Companies and a Leading Genomics Information Company to Advance Treatment for Cancer Affecting 20,000 Americans Annually   (Rye Brook, NY...

LLS Introduces Random Acts of Light

The Leukemia & Lymphoma Society® Introduces Random Acts of Light To Help Bring Moments of Light To Darkness of Cancer   Celebrities Surprise Their Biggest Fans Who Have Been Touched by Blood Cancers   Rye Brook, NY (October 6, 2016) – Today, The Leukemia & Lymphoma Society (LLS) is introducing Random Acts of Light, a new initiative to ...

Burlington and LLS Join Forces for 15th Year to Raise Funds to Fight Cancer

Rye Brook, NY (September 7, 2016) – Did you know that every three minutes, someone in the U.S. is diagnosed with a blood cancer, and more than 1.2 million people in the U.S. are living with, or in remission from, a blood cancer? Unlike many other diseases, there are no means of preventing or screening for blood cancers. Timed to Blood Cancer Awareness Month, Burlington Stores and The Leukemia & Lymphoma Society...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: